505703273 10/02/2019 PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT5750083

		NEW ASSIGNMENT	
ATURE OF CONVEYAN	NCE:	ASSIGNMENT	
CONVEYING PARTY DA	ΑΤΑ		
		Name	Execution Date
MAGNUS OXYGEN LIM	ITED		10/19/2017
RECEIVING PARTY DA	ТА		
Name:	MERV	YN SINGER	
Street Address:	16 COF	PPICE WALK, TOTTERIDGE	
City:	LONDO	N	
State/Country:	ENGLA	ND	
Postal Code:	N20 8B	Z	
Name:	ALEX [DYSON	
Street Address:	39 PAL	MERSTON ROAD	
City:	LONDO	N	
State/Country:	ENGLA	ND	
Postal Code:	N22 8C	λΗ	
PROPERTY NUMBERS			
PROPERTY NUMBERS Property Type		Number	
Property Type		Number 13630180	
Application Number: CORRESPONDENCE D Fax Number: Correspondence will be using a fax number, if p Phone: Email: Correspondent Name: Address Line 1:	ATA e sent to provideo	13630180 <i>the e-mail address first; if that is u</i> <i>i; if that is unsuccessful, it will be s</i> 3523758100 DRS@SLEPATENTS.COM DAVID R. SALIWANCHIK P.O. BOX 142950	sent via US Mail.
Property Type Application Number: CORRESPONDENCE D Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1:	ATA e sent to provideo	13630180 5 the e-mail address first; if that is used i; if that is unsuccessful, it will be so 3523758100 DRS@SLEPATENTS.COM DAVID R. SALIWANCHIK	sent via US Mail.
Property Type Application Number: CORRESPONDENCE D Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4:	ATA e sent to provideo	13630180 <i>the e-mail address first; if that is u</i> <i>i; if that is unsuccessful, it will be s</i> 3523758100 DRS@SLEPATENTS.COM DAVID R. SALIWANCHIK P.O. BOX 142950	sent via US Mail.
Property Type Application Number: CORRESPONDENCE D Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1:	ATA e sent to provideo	13630180 o the e-mail address first; if that is used if that is unsuccessful, it will be so 3523758100 DRS@SLEPATENTS.COM DAVID R. SALIWANCHIK P.O. BOX 142950 GAINESVILLE, FLORIDA 32614-295	sent via US Mail.
Property Type Application Number: CORRESPONDENCE D Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4:	ATA e sent to provideo	13630180 o the e-mail address first; if that is used i; if that is unsuccessful, it will be so 3523758100 DRS@SLEPATENTS.COM DAVID R. SALIWANCHIK P.O. BOX 142950 GAINESVILLE, FLORIDA 32614-295 GJE.8666C1	sent via US Mail.
Property Type Application Number: CORRESPONDENCE D Fax Number: <i>Correspondence will be</i> <i>using a fax number, if p</i> Phone: Email: Correspondent Name: Address Line 1: Address Line 4: ATTORNEY DOCKET NU	ATA e sent to provideo	13630180 b the e-mail address first; if that is used i; if that is unsuccessful, it will be so 3523758100 DRS@SLEPATENTS.COM DAVID R. SALIWANCHIK P.O. BOX 142950 GAINESVILLE, FLORIDA 32614-295 GJE.8666C1 DAVID R. SALIWANCHIK	sent via US Mail.

source=1-exAssign-MO-MS-AD#page1.tif source=1-exAssign-MO-MS-AD#page2.tif source=1-exAssign-MO-MS-AD#page3.tif source=1-exAssign-MO-MS-AD#page4.tif source=1-exAssign-MO-MS-AD#page5.tif source=1-exAssign-MO-MS-AD#page6.tif source=1-exAssign-MO-MS-AD#page7.tif source=1-exAssign-MO-MS-AD#page8.tif source=1-exAssign-MO-MS-AD#page9.tif source=1-exAssign-MO-MS-AD#page10.tif source=1-exAssign-MO-MS-AD#page11.tif source=1-exAssign-MO-MS-AD#page12.tif source=1-exAssign-MO-MS-AD#page13.tif source=1-exAssign-MO-MS-AD#page14.tif source=1-exAssign-MO-MS-AD#page15.tif source=1-exAssign-MO-MS-AD#page16.tif source=1-exAssign-MO-MS-AD#page17.tif

ASSIGNMENT AGREEMENT

between

Magnus Oxygen Limited

and

Mervyn Singer

and

Alex Dyson

Dated:

19" deleber 2012

<?

INDEX

| 1. | Assignment | 2 |
|--------------------|--|----|
| 2. | Warranties, Representations and Undertakings | 4 |
| 3. | Moral Rights | 5 |
|
··· 4 : | Funding and Reservation of Rights | 5 |
| 5. | General | 6 |
| Schedu | le 1 General Description of the Technology | 10 |
| Schedu | le 2 Specific Items of Intellectual Property or Other Property | 1 |
| | | |

......

Śc

THIS AGREEMENT is made the 19 day of October 2017

BETWEEN:

(1) MAGNUS OXYGEN LIMITED, a company incorporated in England with company number 08698373, whose registered address is 26 Red Lion Square, London, England, WC1R 4AG (the "Company");

and

- (2) **PROFESSOR MERVYN SINGER**, whose home address is at 16 Coppice Walk, Totteridge, London, England, N20 8BZ;
- (3) DOCTOR ALEX DYSON, whose home address is at 39 Palmerston Road, London, England N22 8QH

(each an "Inventor" and together, the "Inventors").

WHEREAS:

- A. The Inventors are directors of the Company, and invented and developed technology, materials and/or know-how relating to the technology described in Schedule 1 (the "Technology"). The Technology includes specific items of intellectual property described in Schedule 2, including the various patents and patent applications, the entire portfolio of which was assigned to the Company under an assignment agreement dated 19 October 2017 and all related data and intellectual property rights, including (but not limited to) know how and trade secrets, relating to the Technology (the "Assigned Property").
- B. UCL Business PLC ("UCLB") wishes to take an assignment of the Assigned Property but due to the relationship between the Company and UCLB, UCLB requires that the Company first assigns the Assigned Property to the Inventors, who will subsequently assign the Assigned Property to UCLB. UCLB will then fund the development of the Technology as described in clause 4 of this agreement (the "Funding").
- C. For the purpose of securing the Funding for the further development of the Technology, the Company now wishes to assign back to the Inventors, in equal shares, all of its right, title and interest in the Technology, and the Inventors wish to take an assignment of the Technology in equal shares, subject to and in accordance with the provisions of this Agreement.
- D. The Company and the Inventors have agreed the terms of a revenue sharing agreement to be entered into by the Company and the Inventors on the same date as this Agreement and relating to the continued exploitation of the Technology (the "Revenue Sharing Agreement").

20

NOW IT IS AGREED as follows:

1. ASSIGNMENT

1.1

In consideration of the Inventors executing the Revenue Sharing Agreement and the sum of £1 (one pound sterling) now paid by each of the Inventors to the Company (receipt and sufficiency of which is hereby acknowledged), the Company hereby assigns and transfers to the Inventors in equal shares, absolutely with full title guarantee all of its right, title and interest in the Assigned Property, including (if applicable):

- 1.1.1 in respect of any and each patent comprised within the Assigned Property which has at the date of this agreement been granted ("Patent"):
 - (i) the right to claim priority from such Patent;
 - (ii) the right to file divisional applications based thereon and to prosecute and obtain grant of patent on each and any such divisional application;
 - (iii) the right to extend to or register in, or in respect of, any country or territory in the world each and any of the Patents or any patents granted on any such divisional applications;
 - (iv) the right to extend the term of any Patents or any divisionals thereof; and
 - (v) the right to elect to reject or submit to the competence of the Unitary Patent Court in respect of any Patent pursuant to Article 83(3) of the Agreement on a Unified Patent Court (2013/C 175/01) or to validate any such Patent as a patent that has unitary effect by virtue of Regulation (EU) No 1257/2012.
- 1.1.2 in respect of any and each patent application comprised within the Assigned Property ("Patent Applications"):
 - the right to claim priority from, and to prosecute and obtain grant of patent on, such Patent Application;
 - (ii) the right to file divisional applications based thereon and to prosecute and obtain grant of patent on each and any such divisional application;
 - the right to extend to or register in, or in respect of, any country or territory in the world each and any of the Patent Applications, and any patents granted on any such Patent Applications or any divisionals thereof;
 - (iv) the right to extend the term of any patents granted on any Patent Applications or any divisionals thereof;

ARL001-02 - Patent Assignment Agreement - Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Execution Version)

PATENT REEL: 050602 FRAME: 0296

ζ)

 (v) the absolute entitlement to any patents granted pursuant to any Patent Applications, any patents granted on any such Patent Applications, or any divisionals thereof, and

3

- (vi) the right to elect to reject or submit to the competence of the Unitary Patent Court in respect of any patent granted pursuant to any Patent Application pursuant to Article 83(3) of the Agreement on a Unified Patent Court (2013/C 175/01) or to validate any such patent as a patent that has unitary effect by virtue of Regulation (EU) No 1257/2012;
- 1.1.3 In respect of any and each Patent and Patent Application comprised within the Assigned Property, all rights to bring or defend any claims, actions or proceedings (and to retain any damages recovered), and/or to appeal any award or judgements issued, in respect of any infringement or challenge to validity or entitlement, or any other cause of action arising from ownership, of the Patents, the Patent Applications, or any patents granted pursuant to such Patent Applications, or any divisionals thereof, whether occurring before on or after the date of this Agreement;
- 1.1.4 In respect of each and any invention disclosed or comprised within the Technology, the right to file patent applications for such invention in or in respect of any country or territory in the world.
- 1.2 To the extent that the Assigned Property includes any know-how and technical information protected under the laws governing confidential information and/or trade secrets protected by the EU Trade Secrets Directive (Directive 2016/943):
 - 1.2.1 the Company hereby transfers to the Inventors such rights as it may have in law to prevent the unlawful or unauthorised acquisition, use or disclosure of or access to such know-how, technical information and trade secrets;
 - 1.2.2 to the extent that such rights cannot be, or are not, transferred by virtue of the provisions of Clause 1.2.1, the Company agrees to be joined in any action (whether as claimant or otherwise) brought by the Inventors or its nominee, or to raise proceedings in its own name if required, against any third party that is alleged to have unlawfully acquired, accessed, used or disclosed any trade secret or to be making unauthorised use of, or to have disclosed in breach of an obligation of confidentiality, the know-how and technical information, subject to the Inventors reimbursing the Company for any damages, costs and expenses actually and reasonably incurred in relation to any such action;
 - 1.2.3 subject to Clause 4, and for so long as each of the know-how, technical information and trade secrets remains confidential and is not publicly known (other than as a result of breach of this Clause 1.2.3 by the Company), the Company will neither use

ARL001-02 - Patent Assignment Agreement - Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Execution Version)

51

nor disclose any such know-how, technical information and trade secrets without the prior written consent of the Inventors;

- 1.2.4 the Company warrants that it is not aware of any disclosure of such know-how, technical information and trade secrets to any third party, prior to the date of this Agreement, except under written obligations of confidentiality;
 - 1.2.5 the Company warrants to the Inventors that none of the know-how, technical information or trade secrets constitutes personal data or personally identifiable information; and
 - 1.2.6 if required to do so by the Inventors, the Company will make such acknowledgements to third parties as the Inventors may reasonably require stating that the Inventors own all right in and to such know-how, technical information and trade secrets and that the Company does not retain any ownership rights in such know-how, technical information and trade secrets.
- 1.3 The Company shall provide to the Inventors (promptly on request) all information and documentation and give such assistance (including executing and delivering documents) as the Inventors may require at the expense of the Inventors for the purpose of giving full effect to this agreement, including:
 - 1.3.1 to secure the vesting in the Inventors of all rights in the Technology;
 - 1.3.2 to uphold the Inventors rights in the Technology including the bringing of any actions as contemplated by Clause 1.2.2; and
 - 1.3.3 to bring, make, oppose or defend any claims, actions or challenge to the entitlement, validity or ownership of, and to resolve any guestions concerning, the Technology.

2. WARRANTIES, REPRESENTATIONS AND UNDERTAKINGS

- 2.1 The Company hereby warrants and undertakes to the Inventors that:
 - 2.1.1 so far as it is aware (having made no enquiry of any third parties or conducted any freedom to operate searches), use and exploitation of the Technology will not infringe the intellectual property rights of any third party;
 - 2.1.2 so far as it is aware (having not made any enquiries of any third parties), the Technology is not subject to any claims, proceedings, challenges or litigation (whether actual, pending or threatened) relating to ownership or validity and is not subject to any third party right or encumbrances;
 - 2.1.3 it has not by act or omission caused or permitted anything which might jeopardise the registration or enforceability or application for registration of any registerable intellectual property comprised within the Technology;

- 2.1.4 all costs associated with the maintenance and prosecution of the Patents and Patent Applications up to the date of this agreement have been paid by the Company;
- 2.1.5 it has not been and is not currently a party to any agreement or understanding, whether oral or written which would in any manner be inconsistent with the assignment of rights provided for in this Agreement;
- 2.1.6 during the term of this agreement it shall not enter into any agreement or understanding, oral or written, nor engage in any activity, which would in any manner be inconsistent with the provisions of this Agreement; and
- 2.1.7 all materials described in Schedule 1 (if any) have been obtained in compliance with all ethical and legal requirements (including applicable data privacy laws, including the Data Protection Act 1998).
- 2.2 Each Inventor acknowledges and agrees that he is aware of all persons who might have rights in the Technology, including any other persons who were involved in developing the Technology, and any organisations that funded such development of the Technology.
- 2.3 The Inventors acknowledge and agree that they will be jointly and severally responsible for any costs associated with the maintenance and prosecution of the Patents and Patent Applications which fall due after the date of this agreement.

3. MORAL RIGHTS

The Company has obtained irrevocable and unconditional waivers of any moral rights in the Technology to which any of the Company's employees may now or at any future time be entitled under Chapter IV of the Copyright Designs and Patents Act 1988 or any similar provisions of law in any jurisdiction, including the right to be identified, the right of integrity and the right against false attribution.

4. FUNDING AND RESERVATION OF RIGHTS

- 4.1 The assignment of the Assigned Property herein is for the purpose of the Inventors assigning the Assigned Property to UCLB, which has agreed to contribute in the region of £150,000 ("Initial Funding") from Apollo Therapeutics ("Apollo"), the full amount of which shall be paid by no later than 1 August 2018 ("Initial Funding Date") to further develop the Technology. In the event that the Initial Funding is not received by the Initial Funding Date, the Inventors shall assign the Assigned Property back to the Company, and shall do all acts reasonably requested by the Company to effect the assignment back to the Company of the Assigned Property.
- 4.2 In addition to the Initial Funding, UCLB will seek a further funding from its Apollo Fund ("Apollo Funding") of no less than £1.75 million pounds sterling to invest in the further development of the Technology following the Initial Funding. In the event that UCLB is unable to secure the

ARL001-02 - Patent Assignment Agreement - Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Execution Version)

51

Apollo Funding by 1 August 2019 ("Apollo Funding Date"), the parties agree that the Inventors shall permit UCLB to obtain alternative funding of no less than £1.75 million pounds sterling ("Alternative Funding"), provided the Alternative Funding is fully committed within 12 months of the Apollo Funding Date ("Alternative Funding Date").

- 4.3 In the event that UCLB does not secure the Apollo Funding by the Apollo Funding Date or the Alternative Funding by the Alternative Funding Date, of it UCLB decides not to seek the Alternative Funding, the Inventors shall assign the Assigned Property back to the Company, and the Inventors shall do all acts reasonably requested by the Company to effect the assignment back to the Company of the Assigned Property.
- 4.4 If UCLB successfully obtains the Apollo Funding, but the Apollo Fund decides within two years of the Apollo Funding Date not to continue investing in the development of the Technology, the parties agree that UCLB shall be permitted to seek additional funding from third parties of no less than £1.75 million, or such other greater amount as may be necessary to fund a Phase II clinical trial of the Technology ("Phase II Funding").
- 4.5 The parties agree that, should the Phase II Funding not be obtained within three years of the Apollo Funding Date or two years of the Alternative Funding Date, the Inventors shall assign the Assigned Property back to the Company, and the Inventors shall do all acts reasonably requested by the Company to effect the assignment back to the Company of the Assigned Property.
- 4.6 The Inventors warrant that they shall ensure any agreements entered into between the Inventors and UCLB shall contain substantially similar provisions to give full effect to this clause 4.
- 4.7 Any assignment of the Assigned Property back to the Company under clauses 4.1, 4.3 and/or 4.5 shall include the assignment of any new intellectual property rights created or developed or used by the Inventors and/or UCLB after the date of this agreement which relate to or are necessary for the further development of the Technology.
- 4.8 The Company shall have the non-exclusive, irrevocable, worldwide, royalty-free right to use the Technology for the Company's own internal research.
- 5. GENERAL

5.1 Amendment.

This agreement may only be amended in writing signed by duly authorised representatives of the Company and the Inventors.

5.2 Assignment.

The Company shall not assign, mortgage, charge or otherwise transfer or deal with any rights or obligations under this agreement without the prior written consent of the Inventors.

5.3 Waiver.

Any waiver given under or in relation to this agreement shall be in writing and signed by or on behalf of the relevant party. No failure or delay on the part of any party to exercise any right or remedy under this agreement shall be construed or operate as a waiver thereof, nor shall any single or partial exercise of any right or remedy preclude the further exercise of such right or remedy.

5.4 Invalid Clauses.

If any provision or part of this agreement is held to be invalid, amendments to this agreement may be made by the addition or deletion of wording as appropriate to remove the invalid part or provision but otherwise retain the provision and the other provisions of this agreement to the maximum extent permissible under applicable law.

5.5 No Agency.

None of the parties shall act or describe itself as the agent of any other party, nor shall any party make or represent that it has authority to make any commitments on any of the other parties' behalf.

5.6 Interpretation.

In this agreement:

- 5.6.1 the headings are used for convenience only and shall not affect its interpretation;
- 5.6.2 references to persons shall include incorporated and unincorporated persons; references to the singular include the plural and vice versa; and references to the masculine include the feminine;
- 5.6.3 references to Clauses and Schedules mean clauses of, and schedules to, this agreement;
- 5.6.4 where the word "including" is used it shall be understood as meaning "including without limitation";
- 5.6.5 this agreement shall be binding on, and enure to the benefit of, each of the Inventors' respective successors, heirs and permitted assigns, and references to the Inventors shall include each of their respective successors, heirs and permitted assigns;
- 5.6.6 any reference to any English law term for any action, remedy, method or judicial proceeding, legal document, legal status, court, official or any legal concept or thing

ARL001-02 - Patent Assignment Agreement - Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Execution Version)

<5

shall in respect of any jurisdiction other than England be deemed to include what most nearly approximates in that jurisdiction to the English law term; and

5.6.7 time shall be of the essence in relation to the performance of the Inventor's obligations under this agreement.

5.7 Law and Jurisdiction.

The validity, construction and performance of this agreement, and any contractual and noncontractual claims arising hereunder, shall be governed by English law and shall be subject to the exclusive jurisdiction of the English courts to which the parties hereby submit.

5.8 Entire Agreement.

The parties acknowledge that they are not relying on any representation, agreement, term or condition which is not set out in this agreement. This agreement, including its Schedules, sets out the entire agreement between the parties relating to its subject matter and supersedes all prior oral or written agreements, arrangements or understandings between them relating to such subject matter. Nothing in this agreement will, however, operate to limit or exclude any liability for fraudulent misrepresentations.

5.9 Third parties.

Unless expressly stated otherwise, this agreement does not create any right enforceable by any person who is not a party to it ("Third Party") under the Contracts (Rights of Third Parties) Act 1999, but this Clause does not affect any right or remedy of a Third Party which exists or is available apart from that Act.

5.10 Announcements.

None of the parties shall make any press or other public announcement concerning any aspect of this agreement without the prior, express written consent of the other parties.

REST OF PAGE LEFT INTENTIONALLY BLANK

8

By Mervyn Singer By Alex Dyson For and on behalf of MAGNUS OXYGEN LIMITED Signature Signature SP Shevens Print name ALEX DYS Print name 64 Print name auric POJT DOCTORAL <u>REJEARCH FELLOW</u> Job title 120 sec. 605 Job title Job title 19 Date TOBER 2017 19/10/2017 OC 2017 Date Final Execution nereren ARL001-02 - Patent Assignment Agreement - Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Draft) 200 PATENT REEL: 050602 FRAME: 0303

This agreement has been executed and takes effect on the date stated at the beginning of it.

SCHEDULE 1

GENERAL DESCRIPTION OF THE TECHNOLOGY

Reperfusion injury (e.g. following heart attack or stroke) is caused by excess production of damaging reactive oxygen species (ROS) due to influx of oxygen following revascularisation. The technology relates to a simple and innovative solution that is highly effective in a laboratory model of myocardial ischaemia/reperfusion injury. Our target population is patients undergoing coronary revascularisation for ST-segment elevation myocardial infarction. We made the novel discovery that a simple inorganic compound, ammonium tetrathiomolybdate (ATTM), used successfully as an unapproved copper chelator for Wilson's disease, is a sulphide donor. This decreases mitochondrial respiration/ROS production and, by releasing sulphide in a unique manner, provides greater efficacy and reduced toxicity over standard sulphide donors. The technology relates to primary development of a novel polymorph of diethylamine tetrathiomolybdate (DEATTM) with therapeutic use of ammonium tetrathiomolybdate (ATTM) as a secondary option. The novel polymorph of DEATTM is synthesized using solid state materials in a process not previously described (Fig 1).



Fig 1: Synthesis of diethylamine tetrathiomolybdate (DEATTM).

50

ARL001-02 - Patent Assignment Agreement - Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Execution Version)

10

SCHEDULE 2

SPECIFIC ITEMS OF INTELLECTUAL PROPERTY

A. All intellectual property rights related to the Technology, including any know how, trade secrets and technical information, and the following patent applications and patents:

| Lase Kei | Instructor's Reference | Country | Application Date | Application No | Publication No. | Registration
Date | Registration
No. | Case Status |
|----------------|--|---------------------------|------------------|---------------------|-----------------|----------------------|---------------------|-----------------------------|
| REP0866BR | TTM for reperfusion injury | Brazil | 30/03/2011 | BR 11 2012 024704 2 | | | | Application filed |
| REPOB666CN | TTM for reperfusion injury | China | 30/03/2011 | 2011800168365 | CN103096903A | | | Examination report received |
| REP03666EP | TTM for reperfusion injury of
the brain | European Patent
Office | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP Granted |
| REP08666EP/AT | TTM for repertusion injury of
the heart | Austria | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| REP08666EP/AT1 | TTM for reperfusion injury of
the brain | Austria | 30/03/2011 | 12189630.2 | 2555834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REP08666EP/BE | TTM for reperfusion injury of the heart | Belgium | 30/03/2011 | 11716826.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| 3EP08666EP/BE1 | TTM for repertusion injury of
the brain | Belgium | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| 3EP08666EP/CH | TTM for reperfusion injury of the heart | Switzerland | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| | | | | | | | | Ń |

| | | | | V | | | | |
|----------------|---|----------------|------------|------------|---------|------------|---------|----------------------------|
| REP08666EP/CH1 | TTM for reperfusion injury of the brain | Switzerland | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REP08666EP/CZ | T.M for reperfusion injury of the heart | Czech Republic | 30/03/2011 | 11718626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Fintered |
| REP08666EP/CZ1 | TTM for repertusion injury of
the brain | Czech Republic | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REP08666EP/DE | TTM for reperfusion injury of the heart | Germany | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| REP08666EP/DE1 | TTM for reperfusion injury of the brain | Germany | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REP08666EP/DE2 | TTM for reperfusion injury of
the kidnøy - Magnus Oxygen | Germany | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | EP National Phase Entered |
| REP08666EP/DK | TTM for reperfusion injury of the heart | Denmark | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| REP08666EP/DK1 | TTM for reperfusion injury of
the brain | Denmark | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REP08666EP/DK2 | TTM for reperfusion injury of
the kidney - Magnus Oxygen | Denmark | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | Granted/Registered |
| REP08666EP/ES | TTM for reperfusion injury of
the heart | Spain | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| REP08666EP/ES1 | TTM for reperfusion injury of
the brain | Spain | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REP08666EP/ES2 | TTM for reperfusion injury of the kidney - Magnus Oxygen | Spain | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | Granted/Registered |
| REP08666EP/FI | TTM for reperfusion injury of
the heart | Finland | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| REP08666EP/FI1 | TTM for repertusion injury of
the brain | Finland | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| 3EP08666EP/FR | TTM for reperfusion injury of
the head | France | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| 3EP08666EP/FR1 | TTM for reperfusion injury of
the brain | France | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |

| 2 TMM for reperificion injury of
henearin miny of
henearin miny of
henearin miny of
henearin miny of
henearin
minor reperificion injury of
henearin
minor reperiment
minor | TM for meenfalion hijny of
he kolmes-wagnus Cryption Fance 30032011 1113-862.6 217042016 842862 TM for meenfalion hijny of
he kolmes-wagnus Cryption Loniex Kingdom 30032011 1171-862.6 255.66534 2011/2014 2864631 TM for meenfalion hijny of
he kolmes-wagnus Cryption Loniex Kingdom 30032011 1171-862.6 286.6534 2011/2014 2866334 TM for meenfalion hijny of
he kolmes Loniex Kingdom 30032011 1171-862.6 286.6534 2011/2014 2866334 TM for meenfalion hijny of
he kolmes Hugpry 30032011 1171-862.6 286.6534 287.042016 282.25661 TM for meenfalion hijny of
he kolmes Hugpry 30032011 1171-862.6 286.122 286.112014 286.112014 286.2461 TM for meenfalion hijny of
he kolmes Loniex Kingdom 30032011 1171-862.6 287.122014 286.2461 TM for meenfalion hijny of
he heat Loniex Kingdom 30032011 1171-862.6 277.042016 287.2666 277.042016 282.26661 777.2014 286.2461 777.20114 286.2461 277.220 | | | | | m | | | | |
|--|---|----------------|---|--------------------------|------------|------------|---------|------------|---------|--------------------------------|
| Immatic construction injury of lunkex Kingdom 3003/2011 117166/26.4 2552461 17712/2014 2556461 Immatic construction injury of lunkex Kingdom 3003/2011 117166/26.4 2552461 2566334 2566334 2566334 25666334 25666334 25666334 25666334 25666334 25666334 25666334 25666334 25666334 25666334 25666334 25666334 2 25666334 25666334 2 25666334 2 25666334 2 25666334 2 25666334 2 25666334 2 25666334 2 25666334 2 25666334 2 2 25666334 2 2 25666334 1 | 3 1111 Micromerication injory of
intermediation injory o | REP08666EP/FR2 | TTM for reperfusion injury of
the kidney - Magnus Oxygen | France | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | EP National Phase Entered |
| 11 Tim for repertusion hund of
the brain Unded Kingdom 300232011 12186630.2 256663.4 26111201.4 256663.4 1 11 The form Tim for repertusion hund of
the brain Hungary 30032011 11176626.4 255565.2 2564515 255663.4 2 11 Tim for repertusion hund of
the brain Hungary 30032011 1177626.4 2553.461 17712014 2555633.4 1 11 Tim for repertusion hund of
the brain Hungary 30032011 1177626.4 2555.461 17712014 2555633.4 1 11 Tim for repertusion hund of
the brain Hungary 30032011 1177626.4 255.663.4 26117014 255.563.4 1 11 Tim for repertusion hund of
the brain Hundary of Hundary 30032011 1177626.4 255.663.4 26117014 255.563.4 1 11 Hor 30032011 1177626.4 256.2461 17712014 255.565.663.4 26117014 255.565.663.4 261172014 255.565.663.4 261172014 255.565.663.4 | 11. Titt för röperfulsion rigury of
in merentision rigury of
in merentision rigury of
the kolorey. Magnus Oxygen
in the kolorey kolorey. Magnus Oxygen
in the kolorey. Magnus Ox | REP08666EP/GB | TTM for reperfusion injury of
the heart | United Kingdom | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 7657484 | |
| R TTM for repertation injury of
ite indicary. Magnus Oxygen United Kingdom 30003/2011 1413482.0.6 284,256.2 27104/2016 284,256.2 2 It Te Main repertation injury of
the heart Hungary 30003/2011 11716528.4 255.461 1771/2014 255.8663 1 1771/2014 255.86683 1 1771/2014 < | 2 TTM for reperifusion injuy of
its relative - Magnus Oxgeni
in TTM for reperifusion injuy of
its relative - Magnus Oxgeni
in TTM for reperifusion injuy of
its relative - Magnus Oxgeni
in TTM for reperifusion injuy of
its reperiment. 284,256,2 253,246,5 253,246, | REP08666EP/GB1 | TTM for reperfusion injury of
the brain | Unted Kingdom | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| Interferentiation injury of
the heart. Hungary 300332011 11716526.4 2552461 17/122014 2552461 2 ITM for reperfusion injury of
the heart. Hungary 300332011 11716526.4 2555461 17/122014 2555833 1 ITM for reperfusion injury of
the heart. Hungary 300332011 11716526.4 2555451 17/122014 25558633 1 ITM for reperfusion injury of
the heart. Haly 300332011 11716526.4 2555451 17/122014 2556833 1 ITM for reperfusion injury of
the heart. Haly 300332011 11716526.4 25552451 17/122014 2556833 1 1 ITM for reperfusion injury of
the heart. Haly 300332011 11716526.4 2552461 17/122014 2556833 2 ITM for reperfusion injury of
the heart. Haly 300332011 11716526.4 2553461 17/122014 25563634 2 ITM for reperfusion injury of
the heart. Lithuania 30032011 11716526.4 2553461 17/122014 25563461 17/122014 | In Tim for repertusion injury of
the heat Hungary 3003/2011 11716626.4 2552.461 17/12/014 243461 243461 In Tim for repertusion injury of
the heat Hungary 3003/2011 11716626.4 2553461 265334 265334 265334 26511/2014 2833663 1 ITM for repertusion injury of
the heat Hungary 3003/2011 11716626.4 25536334 26711/2014 25536634 1 ITM for repertusion injury of
the heat Hay 3003/2011 11716626.4 2553634 26711/2014 2553461 1 ITM for repertusion injury of
the heat Hay 3003/2011 11716626.4 2552461 17712/2014 2553461 1 ITM for repertusion injury of
the heat Hay 3003/2011 11716626.4 2552461 1771/2014 2553461 1 Ith for repertusion injury of
the heat Libruania 3003/2011 11716626.4 2552461 1771/2014 2552461 1 2771/2014 2552461 1 2771/2014 2552461 1 2771/2014 25524661 1 | REP08666EP/GB2 | TTM for repertusion injury of
the kidney - Magnus Oxygen | United Kingdom | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | EP National Phase Entered |
| It TIM for repertusion injury of
the brain Hungary 30/03/2011 12180630.2 2556683.4 2611/2014 255688.4 1 TIM for repertusion injury of
the brain teal 30/03/2011 11716526.4 2556683.4 2652461 17712/2014 2552461 2556883.4 2 TIM for repertusion injury of
the brain taaly 30/03/2011 12188630.2 2556683.4 2652461 17712/2014 25528683.4 2 TIM for repertusion injury of
the brain taaly 30/03/2011 12188630.2 2556683.4 2611/2014 25528683.4 2 TIM for repertusion injury of
the brain taaly 30/03/2011 14194820.8 2652461 17712/2014 2555883.4 2 TIM for repertusion injury of
the brain tall 30/03/2011 11716626.4 255683.4 26111/2014 2555883.4 E E TIM for repertusion injury of
the brain the brain 30/03/2011 12176626.4 255683.4 26111/2014 255683.4 E E TIM for repertusion injury of
the brain the brain 30/03/2011 | Intention TIM for repertuation injury of
the brain Hungary
(her brain 30032011 12186530 2 2566834 261112014 2555361 1 ITM for repertuation injury of
the brain text 30032011 11716253.4 2553461 177122014 2553863.4 1 ITM for repertuation injury of
the brain text 30032011 11716525.4 2556653.4 261112014 25552661 1 1 ITM for repertuation injury of
the brain text 30032011 11716526.4 2555461 177122014 2555363.4 1 ITM for repertuation injury of
the brain text 30032011 14194820.6 2842662 2704/2016 2455936.4 1 ITM for repertuation injury of
the brain text 30032011 1717662.4 2552461 1771/2014 255383.4 1 ITM for repertuation injury of
the brain text 30032011 1171662.4 2552461 1771/2014 255383.4 1 255383.4 1 255383.4 1 2555383.4 1 2555383.4 2555383.4 1 2555383.4 | (EP08666EP/HU | TTM for reperfusion injury of the heart | Hungary | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | FB National Dhace Enterna |
| Till för reperfusion injury of
the heart. Till för reperfusion injury of
the brain. Laly 30/03/2011 11716626.4 2652461 77122014 25552461 25552461 25552461 25552461 25552461 25552461 255523461 255523461 255523461 25555334 2 255523461 255523461 255523461 255523461 2 255523461 2 255523461 2< | TTM for repertusion injury of
the heart. Italy 3003/2011 I1/16/26.4 255/2461 I7/12/2014 255/2461 TTM for repertusion injury of
the prain. TTM for repertusion injury of
the prain. Italy 30/03/2011 I1/16/26.4 255/26.5 256/26.5 256/26.5 I TTM for repertusion injury of
the brain. Italy 30/03/2011 I1/16/26.6 284/25.5 27/04/2016 284/25.6 I I TTM for repertusion injury of
the brain. Italy 30/03/2011 I1/16/26.6 255/66.5 I I 265/246.1 I I 265/26.5 I I I 265/246.1 I 265/26.5 I I I I I I I 265/246.1 I I I I I I 265/246.1 I | EP08666EP/HU1 | TTM for reperfusion injury of the brain | Hungary | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| TM for repertusion injury of
the brain taty 30/03/2011 12186530.2 2556834 26/11/2014 2556834 TM for repertusion injury of
the brain taty 30/03/2011 12189630.2 2556834 26/11/2014 2556834 TM for repertusion injury of
the brain taty 30/03/2011 14194820.8 2842562 27/04/2016 2842562 TM for repertusion injury of
the brain Lithuania 30/03/2011 11716626.4 2552461 17/12/2014 2552461 TM for repertusion injury of
the brain Lithuania 30/03/2011 12189630.2 2556834 26/11/2014 2552461 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/12/2014 2552461 17/1 | TTM for repertation injury of
the brain Italy 30/03/2011 12189630.2 2556834 261/1/2014 2556834 EP National Phase Enti-
ter National Phase Enti-
Statistic Statistic | EP08666EP/IT | TTM for reperfusion injury of
the heart | Italy | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| TTM for reperfusion injury of
the kidney - Wagmus Oxygen tany
tank 30/03/2011 14194820.8 2842562 27/04/2016 2842562 TTM for reperfusion injury of
the beart Lithuania 30/03/2011 14716626.4 2552461 17/12/2014 2555834 TTM for reperfusion injury of
the brain Lithuania 30/03/2011 11716626.4 25556834 26/11/2014 2555834 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2555461 17/12/2014 2555834 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2555461 17/12/2014 2555461 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2555461 17/12/2014 2555461 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2555461 17/12/2014 2555461 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 12189630.2 2555461 17/12/2014 25552461 17/12/2014 25552461 17/12/2014 25552461 17/12/2014 | TTM for reperfusion injury of
the kidney - Magnus Cxygen Italy
the kidney - Magnus Cxygen Cidney - Magnus Cxygen Lindex Cx Italy
the bid Italy
the kidney - Magnus Cxygen Lindex Cx Italy
the bid | EP08686EP/IT1 | TTM for reperfusion injury of
the brain | italy | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2558834 | EP National Phase Entered |
| TTM for reperfusion injury of
the heart Lithuania 30/03/2011 11716626.4 2552451 17/12/2014 2552461 TTM for reperfusion injury of
the brain Lithuania 30/03/2011 11716626.4 25556834 25/11/2014 2556834 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 12189630.2 2556834 26/11/2014 2552461 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2552461 17/12/2014 2556334 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2555461 17/12/2014 25552461 TTM for reperfusion injury of
the brain Macedonia 30/03/2011 12189630.2 2555461 17/12/2014 25552461 TTM for reperfusion injury of
the heart Netherlands 30/03/2011 12189630.2 2552461 17/12/2014 25552461 TTM for reperfusion injury of
the heart Netherlands 30/03/2011 12189630.2 2552461 17/12/2014 25552461 1 TTM for reperfusion injury of
the heart Netherlands 30/03/2011 <td>TTM for reperfusion injury of
the heartLiftuania30/03/201111716526.4255246117712/20142552461EP National Phase EntiTTM for reperfusion injury of
the brainLiftuania30/03/201111716526.4255683426/11/20142556834EP National Phase EntiTTM for reperfusion injury of
the brainMacedonia
(F Y R.O.M)30/03/201111716526.4255246117712/201425556834EP National Phase EntiTTM for reperfusion injury of
the heartMacedonia
(F Y R.O.M)30/03/201111716526.4255546117712/201425556334EP National Phase EntiTTM for reperfusion injury of
the heartMacedonia
(F Y R.O.M)30/03/201111716526.4255546117712/201425556334EP National Phase EntiTTM for reperfusion injury of
the heartNetherlands30/03/201111716526.4255546117712/201425556334EP National Phase EntiTTM for reperfusion injury of
the heartNetherlands30/03/201111716526.4255546117712/201425566334EP National Ph</td> <td>EP08666EP/IT2</td> <td>TTM for repertusion injury of
the kidney - Magnus Oxygen</td> <td>łłały</td> <td>30/03/2011</td> <td>14194820.8</td> <td>2842562</td> <td>27/04/2016</td> <td>2842562</td> <td>Granted/Registered</td> | TTM for reperfusion injury of
the heartLiftuania30/03/201111716526.4255246117712/20142552461EP National Phase EntiTTM for reperfusion injury of
the brainLiftuania30/03/201111716526.4255683426/11/20142556834EP National Phase EntiTTM for reperfusion injury of
the brainMacedonia
(F Y R.O.M)30/03/201111716526.4255246117712/201425556834EP National Phase EntiTTM for reperfusion injury of
the heartMacedonia
(F Y R.O.M)30/03/201111716526.4255546117712/201425556334EP National Phase EntiTTM for reperfusion injury of
the heartMacedonia
(F Y R.O.M)30/03/201111716526.4255546117712/201425556334EP National Phase EntiTTM for reperfusion injury of
the heartNetherlands30/03/201111716526.4255546117712/201425556334EP National Phase EntiTTM for reperfusion injury of
the heartNetherlands30/03/201111716526.4255546117712/201425566334EP National Ph | EP08666EP/IT2 | TTM for repertusion injury of
the kidney - Magnus Oxygen | łłały | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | Granted/Registered |
| TIM for reperfusion injury of
the brain Lithuania 30/03/2011 f12189530.2 2556834 26/11/2014 2556834 TIM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2552461 17/112/2014 2552834 TIM for reperfusion injury of
the brain Macedonia 30/03/2011 11716626.4 2552461 17/112/2014 2556834 TIM for reperfusion injury of
the brain Macedonia 30/03/2011 12189630.2 2552461 17/112/2014 2555834 TIM for reperfusion injury of
the brain Metherlands 30/03/2011 12189630.2 2552461 17/112/2014 2555834 TIM for reperfusion injury of
the brain Netherlands 30/03/2011 12189630.2 25552461 17/112/2014 25552461 1 Tim for reperfusion injury of
the brain Netherlands 30/03/2011 12189630.2 2556834 26/11/2014 25552461 1 | TIM for reperfusion injury of
the brain Lithuania 30/03/2011 12189630.2 255683.4 26/11/2014 255683.4 EP Mational Phase Ent
to heart TIM for reperfusion injury of
the brain F Y R.O.M) 30/03/2011 11716526.4 2552461 17/12/2014 2552451 EP Mational Phase Ent
to heart TIM for reperfusion injury of
the brain F Y R.O.M) 30/03/2011 12189630.2 255583.4 26/11/2014 2552461 EP Mational Phase Ent
to heart TIM for reperfusion injury of
the brain Macedonia 30/03/2011 12189630.2 2555461 17/12/2014 2552461 EP Mational Phase Ent
to heart TIM for reperfusion injury of
the brain Netherlands 30/03/2011 12189630.2 2555461 17/12/2014 2552461 EP Mational Phase Ent
to heart TIM for reperfusion injury of
the brain Netherlands 30/03/2011 12189630.2 2556834 26/11/2014 2552461 EP Mational Phase Ent
to heart TIM for reperfusion injury of
the brain Netherlands 30/03/2011 12189630.2 2556834 26/11/2014 2556834 EP Mational Phase Ent
to heart 10.7 | EP08666EP/LT | TTM for reperfusion injury of
the heart | Lithuania | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | ED Mations(Discover Easterney |
| TTM for repertusion injury of
the heart Maccedonia 30/03/2011 11716626.4 2552461 17712/2014 2552461 I TTM for repertusion injury of
the brain Maccedonia 30/03/2011 12189630.2 2556834 26/11/2014 2556834 I TTM for repertusion injury of
the brain Metherlands 30/03/2011 12189630.2 2556834 26/11/2014 2556834 I TTM for repertusion injury of
the brain Netherlands 30/03/2011 11716626.4 2552461 17/12/2014 2552461 I TTM for reperfusion injury of
the brain Netherlands 30/03/2011 12189630.2 2552461 17/12/2014 2552461 | TIM for reperfusion injury of the heart Macedonia 30/03/2011 11716626.4 2552461 17/12/2014 2552461 EP National Phase Entrance In TIM for reperfusion injury of the heart (F.Y.R.O.M) 30/03/2011 121896530.2 25556834 26/11/2014 25566334 EP National Phase Entrance TIM for reperfusion injury of the heart (F.Y.R.O.M) 30/03/2011 11716626.4 2555461 17/112/2014 2556834 EP National Phase Entrance TIM for reperfusion injury of the heart Netherlands 30/03/2011 11716626.4 2555461 17/112/2014 2556834 EP National Phase Entrance TIM for reperfusion injury of the brain Netherlands 30/03/2011 121896530.2 2555461 17/112/2014 2552461 EP National Phase Entrance TIM for reperfusion injury of the brain Netherlands 30/03/2011 121896530.2 2555461 17/11/2014 2552461 EP National Phase Entrance To brain Time brain Netherlands 30/03/2011 121896530.2 2555834 26/11/2014 2552461 EP National Phase Entrance To brain Time brain 2556834 26/11/2014 2556834 EP National Phase E | EP08666EP/LT1 | TTM for reperfusion injury of the brain | Lithuania | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | ED Notional Dhace Entered |
| TTM for repertusion injury of Macedonia 30/03/2011 12189630.2 2556834 26/11/2014 2556834 TTM for repertusion injury of the heart Netherlands 30/03/2011 11716626.4 2552461 17/12/2014 2556834 TTM for repertusion injury of the heart Netherlands 30/03/2011 11716626.4 2552461 17/12/2014 2552461 TTM for repertusion injury of the heart Netherlands 30/03/2011 12189630.2 2556834 2552461 2556834 | 1 TIM for reperfusion injury of the brain (F Y R.O.M) 30/03/2011 12189630.2 2556834 26/11/2014 2556834 EP National Phase Entrance 1 TIM for reperfusion injury of the brain | EPO8666EP/MK | TTM for reperfusion injury of
the heart | Macedonia
(F.Y.R.O.M) | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2557461 | ED Motional Dhase Cillered |
| TIM for repertusion injury of Netherlands 30/03/2011 11716626.4 2552461 17/12/2014 2552461 TIM for reperfusion injury of the brain Netherlands 30/03/2011 12189630.2 2556834 2556834 | TIM for reperfusion injury of
the heart Netherlands 30/03/2011 11716628.4 2552451 17/12/2014 2552461 EP National Phase Emit TFM for reperfusion injury of
the brain Netherlands 30/03/2011 121896330.2 2556834 256/11/2014 2556834 EP National Phase Emit 1-0.2 - Patent Assignment Agreement – Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Execution Version) 2556834 25/11/2014 2556834 EP National Phase Emit | EP08666EP/MK1 | TTM for repertusion injury of
the brain | Macedonia
(F_Y.R.O.M) | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EL National Class Cittered |
| TFM for reperfusion injury of Netherlands 30/03/2011 12189630.2 2556834 26/11/2014 2556834 | T IM for reperfusion injury of the brain Netherlands 30/03/2011 12189630.2 2556834 26/11/2014 2556834 EP National Phase Enter the brain 1-02 Patent Asignment Agreement – Magnus Oxygen Limited to Mervyn Singer and Alex Dyson (Final Execution Version) 2556834 25/11/2014 2556834 EP National Phase Enter the brain | EPO8666EP/NL | TTM for repertusion injury of the heart | Netherlands | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2559461 | ED National Fridade Entered |
| | | EP08666EP/NL1 | TFM for reperfusion injury of the brain | Netherlands | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |

PATENT REEL: 050602 FRAME: 0307

| REP08666EP/NL2 | TTM for repertusion injury of
the kidney - Magnus Oxygen | Netherlands | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | Crontood/Downstates |
|----------------|---|-------------|------------|-------------|----------|----------------|----------|--|
| REP08666EP/NO | TTM for repertusion injury of the head | Norway | 30,03/2014 | 41746672 4 | | | | |
| | TTM for reneringion initial of | | 110300.80 | 11 10020.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| KEPU8666EP/NO1 | the brain | Norway | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REPO3666EP/PL | TTM for repertusion injury of
the heart | Poland | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered |
| REP08666EP/PL1 | TTM for reperfusion injury of
the brain | Poland | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP National Phase Entered |
| REP08666EP/PT | TTM for reperfusion injury of the heart | Portugal | 30/03/2011 | 11716626.4 | 2552461 | ×100/01/21 | Percago | |
| REP08666EP/PT1 | TTM for reperfusion injury of
the brain | Portugal | 30/03/2011 | 12189630.0 | JEER004 | | 10477077 | EP National Phase Entered |
| REP08666EP/SE | TTM for reperfusion injury of | Sweden | 30/03/2014 | | 100000-1 | 401 E 81 ZU 14 | 2556834 | EP National Phase Entered |
| REDUSESED/CE4 | TTM for reperfusion injury of | | | * 02001 111 | 1047007 | 17/12/2014 | 2552461 | EF National Phase Entered |
| | the brain | Sweden | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2555834 | EP National Phase Entered |
| REP08666EP/SE2 | TTM for repertusion injury of
the kidney - Magnus Oxygen | Sweden | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | Granted/Registered |
| REP08666EP/SI | TTM for reperfusion injury of the heart | Siovenia | 30/03/2011 | 11715626.4 | 2552461 | 17/12/2014 | 2552461 | ED Motional Director |
| REP08666EP/SI1 | TFM for reperfusion injury of the brain | Slovenia | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 755823A | |
| REP08666EP/SK | TTM for reperfusion injury of the heart | Stovakia | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2550000 | |
| REP08666EP/SK1 | TTM for reperfusion injury of the brain | Slovakia | 30/03/2011 | 12189630.2 | 2556834 | 06/11/004A | 2555034 | Cr Nauonal Phase Entered |
| REP08666EP/TR | ³ TM for reperfusion injury of
the heart | Turkey | 30/03/2011 | 11716626.4 | 2552461 | 17/12/2014 | 2552461 | EP National Phase Entered
EP National Phase Entered |

| 1 TTM for reservation injury of
the heart. Algonis Coygan European Patent 3003/2011 1/2169530.2 2556834 26/11/2014 2555634 2 TTM for reservation injury of
he killing. Maginis Coygan European Patent 3003/2011 1/164820.6 28/4256/2 22/04/2016 28/4256/2 2 TTM for reservation injury of
he killing. Maginis Coygan European Patent 3003/2011 1/164820.6 28/4256/2 22/04/2016 28/4256/2 3 TTM for reservation injury of
the heart. European Patent 3003/2011 1/154/5 28/4256/2 2/104/2016 28/4256/2 2 3 TTM for reservation injury of
the heart. Jonan 3003/2011 2013-50194/1 2013-527109 08/01/2015 68/426/2 2 1 TTM for reservation injury of
the heart. Jonan 30/03/2011 2013-523709 08/01/2015 68/48/17 7 7 1 TTM for reservation injury of
the heart. Joean 30/03/2011 2013-52/1490 11/11/2015 68/48/17 7 7 1 TTM for reperfusion injury of
the heart. Joean </th <th>Introduction injury of
her frager fusion injury of
fusions Exercises a
base 2000/2001 1/1 (1948/2013 256665/4 284/1/2014 256689/4 2 TMM for reperfusion injury of
fusions European Plant 300/3/2011 1/1 (1948/2013 284/2662 284/1/2014 256689/4 3 TMM for reperfusion injury of
fusions European Plant 300/3/2011 1/1 (1948/2013 284/2662 284/1/2014 284/2662 3 TMM for reperfusion injury of
fusions Lapan 300/3/2011 2013-6019/4/1 2013-657/450 1/1 (1/1/2016 60/3/8667 0 1 TM for reperfusion injury of
fusions Japan 300/3/2011 2014-256628 2015-57/450 1/1 (1/1/2016 62/36677 0 1 M for reperfusion injury of
the heart. Magnus Crygen Japan 300/3/2011 2014-256628 2011/1/12016 62/36677 0 0 0 1 TM for reperfusion injury of
the heart. Magnus Crygen Japan 300/3/2011 2014-256628 <td< th=""><th>TH for repertision highly of
intermediation highly of
the tear. Exercised
for tear. 266112014 2566804 TH for repertision highly of
the hear. Circipan Patent 30032011 1/184203 2662622 266112014 2566804 TH for repertision highly of
disasse Circipan Patent 30032011 1/184203 2842562 2/04/2016 2842562 TH for repertision highly of
disasse Circipan Patent 30032011 1/184203 2842563 2/04/2016 2842562 TH for repertision highly of
the heat. Circipan Patent 30032011 2/01560140 2015-671400 2/015-67160 TH for repertision highly of
the heat. Line is constrained 30032011 2/015-671400 0/00/7016 6/042601 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/12/016 6/026607 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/12/016 6/026667 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/11/12/016 6/036677 0 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 1/11/11/2016 6/036677 0 TH for repertision highly of
the heat. More repertision highly of
the heat.</th><th>REP08666EP/TR1</th><th>TTM for reperfusion injury of
the brain</th><th>Turkey</th><th>30/03/2011</th><th>12189630.2</th><th>2556834</th><th>26/11/2014</th><th>2656834</th><th>EP National Phase Cotana</th></td<></th> | Introduction injury of
her frager fusion injury of
fusions Exercises a
base 2000/2001 1/1 (1948/2013 256665/4 284/1/2014 256689/4 2 TMM for reperfusion injury of
fusions European Plant 300/3/2011 1/1 (1948/2013 284/2662 284/1/2014 256689/4 3 TMM for reperfusion injury of
fusions European Plant 300/3/2011 1/1 (1948/2013 284/2662 284/1/2014 284/2662 3 TMM for reperfusion injury of
fusions Lapan 300/3/2011 2013-6019/4/1 2013-657/450 1/1 (1/1/2016 60/3/8667 0 1 TM for reperfusion injury of
fusions Japan 300/3/2011 2014-256628 2015-57/450 1/1 (1/1/2016 62/36677 0 1 M for reperfusion injury of
the heart. Magnus Crygen Japan 300/3/2011 2014-256628 2011/1/12016 62/36677 0 0 0 1 TM for reperfusion injury of
the heart. Magnus Crygen Japan 300/3/2011 2014-256628 <td< th=""><th>TH for repertision highly of
intermediation highly of
the tear. Exercised
for tear. 266112014 2566804 TH for repertision highly of
the hear. Circipan Patent 30032011 1/184203 2662622 266112014 2566804 TH for repertision highly of
disasse Circipan Patent 30032011 1/184203 2842562 2/04/2016 2842562 TH for repertision highly of
disasse Circipan Patent 30032011 1/184203 2842563 2/04/2016 2842562 TH for repertision highly of
the heat. Circipan Patent 30032011 2/01560140 2015-671400 2/015-67160 TH for repertision highly of
the heat. Line is constrained 30032011 2/015-671400 0/00/7016 6/042601 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/12/016 6/026607 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/12/016 6/026667 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/11/12/016 6/036677 0 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 1/11/11/2016 6/036677 0 TH for repertision highly of
the heat. More repertision highly of
the heat.</th><th>REP08666EP/TR1</th><th>TTM for reperfusion injury of
the brain</th><th>Turkey</th><th>30/03/2011</th><th>12189630.2</th><th>2556834</th><th>26/11/2014</th><th>2656834</th><th>EP National Phase Cotana</th></td<> | TH for repertision highly of
intermediation highly of
the tear. Exercised
for tear. 266112014 2566804 TH for repertision highly of
the hear. Circipan Patent 30032011 1/184203 2662622 266112014 2566804 TH for repertision highly of
disasse Circipan Patent 30032011 1/184203 2842562 2/04/2016 2842562 TH for repertision highly of
disasse Circipan Patent 30032011 1/184203 2842563 2/04/2016 2842562 TH for repertision highly of
the heat. Circipan Patent 30032011 2/01560140 2015-671400 2/015-67160 TH for repertision highly of
the heat. Line is constrained 30032011 2/015-671400 0/00/7016 6/042601 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/12/016 6/026607 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/12/016 6/026667 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 0/01/11/11/12/016 6/036677 0 TH for repertision highly of
the heat. Japan 30032011 2/015-671400 1/11/11/2016 6/036677 0 TH for repertision highly of
the heat. More repertision highly of
the heat. | REP08666EP/TR1 | TTM for reperfusion injury of
the brain | Turkey | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2656834 | EP National Phase Cotana |
|---|--|---|-------------------|--|--|------------|-------------------|---------------|------------|---------|----------------------------------|
| 2TTM for repertuision injury of
the kutiney - Magnus OxygenEuropeen Petent30033/201114194320.6234256227704/201629425623TTM for repertusion injury of
the heart.Europeen Petent3003/201114194320.6264256227704/201629425623TTM for repertusion injury of
the heart.Europeen Petent3003/201110003584.01001354.011/11/201620425621TTM for repertusion injury of
the heart.Japan3003/20112013-5016472013-5574500901/201566749171TTM for repertusion injury of
the heart.Japan3003/20112014-2568282015-5745011/11/201680286671TTM for repertusion injury of
the heart.Japan3003/20112014-2568282015-574509901/201566749171TTM for repertusion injury of
he heart.Japan3003/20112014-2568282015-5745011/11/201666749171TTM for repertusion injury of
he heart.United States of
Contactor Use3003/201112/6501602013-0171/11/2136411/11/21/841TTM fo | 2TMM for reperfusion mujury of
the kidney. Magnus OxygenEuropean Patent30.00.2/2011141 et 442.0.8264.266.227.04/2016284.256.23TMM for reperfusion mujury of
diseaseEuropean Patent30.00.2/201110.05.344.02014.22014.22014.21TMM for reperfusion mjury of
the hadriUnited Kingtoon30.00.2/20112013.501.1042013.52.70100.0001/2015567.41TMM for reperfusion mjury of
the hadriUnited Kingtoon30.003/20112013.501.1042013.52.77090.001/2015567.41TMM for reperfusion mjury of
the hadriJapan30.003/20112013.501.1012013.52.77090.001/2015567.41TMM for reperfusion mjury of
the hadriJapan30.003/20112014.2686.282015.57.45011111/2016603.66671TMM for reperfusion mjury of
the hadriMascelaneous30.003/20112014.2686.282015.57.45011111/2016603.66771TMM for reperfusion mjury of
the hadriUnited Kimeled Latei30.003/20112014.2686.282015.57.45011111/11/2016603.66771TMM for reperfusion mjury of
the hadriMascelaneous30.003/2011136501602015.57.45011111/11/2016603.66771TMM for reperfusion mjury of
the hadriMascelaneous30.003/2011136501602015.57.45011111/11/2016603.66771TMM for reperfusion mjury of
the headMascelaneous30.003/2011136501602015.57.45011 | 2 TWN for repertusion injury of
the kidney - Wagnus Coygen European Patient 30003/2011 14184820.8 2842562 27/64/2016 2842562 3 TWN for repertusion injury of
datasets European Patient 30003/2011 14184820.8 2842562 27/64/2016 2842562 1 TWN for repertusion injury of
the haart European Patient 30003/2011 2013-623709 0901/2015 587497 1 TWN for repertusion injury of
the heart Japan 30003/2011 2013-623709 0901/2015 5034377 1 TWN for repertusion injury of
the heart Japan 30003/2011 2014-236828 2015-653709 0901/2015 60336677 1 TWN for repertusion injury of
the heart Japan 30003/2011 2013-623709 0901/2015 6034307 1 TWN for repertusion injury of
the heart Japan 30003/2011 2014-236828 2015-653709 0901/2015 6034307 1 TWN for repertusion injury of
the heart Maceilaneous 30003/2011 2014-236828 2015-653709 0901/2015 6034377 1 TWN for repertusion injury of
the heart Maceilaneous 30003/2011 2014-236828 2015-657490 11/11/2016 6036867 1 TWN for repertusion injury Marefial | REP08666EP1 | TTM for reperfusion injury of
the heart - Magnus Oxygen | European Patent
Office | 30/03/2011 | 12189630.2 | 2556834 | 26/11/2014 | 2556834 | EP Granted |
| 3 Tim for perifyieral artery Eucopean Patent 300332011 300332011 1 Tim for reperfusion injury of
the mart. Magnus Oxygen Unleed kingdom 30032011 2015-573709 090012015 6574917 1 Tim for reperfusion injury of
the heart Japan 300322011 2015-573709 090012015 6574917 1 Tim for reperfusion injury of
the heart Japan 300322011 2014-256628 2015-57450 11/11/2016 6036667 1 Tim for reperfusion injury of
the heart Japan 3003/2011 2014-256628 2015-57450 11/11/2016 6036667 1 Tim for reperfusion injury of
the heart Miscellaneous 3003/2011 2014-256628 2015-57450 11/11/2016 603667 1 Tim for reperfusion injury of
heart Miscellaneous 3003/2011 2014-256628 2015-57450 11/11/12/016 603667 1 Tim for reperfusion injury of
heart Miscellaneous 3003/2011 13/630160 2015-57450 11/11/12/016 603667 1 Tim for reperfusion injury of
heart Miscellaneous 3003/2011 13/630160 2015-57450 11/11/12/016 6036667 1 Tim for reperfusion injury of
heart Miscellaneous 3003/2011 13/630160 2015 | 3 Tim for peripheral artery
disease European Palent 30032011 30032011 Tim for repertation njury of
the heart. Magnus Oxygen United Kingdom 30032011 2013-501947 2013-523709 03001/2015 5674917 Tim for repertation njury of
the beam. Japan 30032011 2013-501947 2013-523709 0301/2015 5674917 Tim for repertation njury of
the brain. Japan 30032011 2013-501947 2013-523709 0301/2015 5674917 Tim for repertation njury of
the brain. Japan 30032011 2013-501947 2013-577450 11/11/12016 503867 Tim for repertation njury of
the brain. Mascellaneous 30032011 2014-258628 2015-577450 11/11/12016 5038667 Tim for repertation njury of
the brain. United States of
Anerica 30032011 2013-50196653 2015-577450 11/11/12016 5033667 Tim for repertation njury of
the brain. United States of
Anerica 30032011 2013-501406 2013-5174595 5013667 5013-5174595 Tim for repertation njury United States of
Anerica 30032011 2013-011721354 5013-617 5013-011121354 Tim for repertation njury United States of
Anerica 2013-5110506553 W020111121354 5013-517 5013-517 | 3 TM for peripheral array
disease Eucrosean Patent
Diffice 3003/2011 3003/2011 3003/2013 TM for repertision njury of
the heart United Kingtom 3003/2011 2015-3014/2 2013-22709 3001/2015 6674917 TM for repertision njury of
the heart Japan 3003/2011 2013-501447 2013-52709 0901/2015 6734917 TM for repertision njury of
the heart Japan 3003/2011 2013-501447 2013-527709 0901/2015 6734917 TM for repertision njury of
the heart Japan 3003/2011 2013-501447 2013-527709 0901/2015 6734917 TM for repertision njury of
the heart Magnus Oxgen Mascellaneous 3003/2011 2013-501447 2013-527709 0901/2015 6734917 TM for repertision njury of
the heart Magnus Oxgen 3003/2011 2014-268628 2015-57450 1111/11/2156 603/2015 TM for repertision njury of
the heart Mascellaneous 3003/2011 2014-268628 2015-57450 1111/11/2156 TM for repertision njury of
the heart TM for repertision njury of
the heart Mostellaneous 3003/2011 2015-57450 1111/11/2156 TM for repertision njury of
the heart Comparition 2015-57450 2015-57450 1111/11/2156 TM for repe | REP08666EP2 | TTM for reperfusion injury of
the kidney - Magnus Oxygen | European Patent
Office | 30/03/2011 | 14194820.8 | 2842562 | 27/04/2016 | 2842562 | EP Granted |
| Till for repertusion hjury of
the heart - Magnus Citygen United Kingdom 3003/2010 100539.4.0 2013-623709 0900/12015 6674917 Till Mor repertusion njury of
the heart - Magnus Citygen Japan 3003/2011 2013-601847 2013-623709 0900/12015 6674917 Till Mor repertusion njury of
the heal Japan 3003/2011 2014-258628 2015-57450 11111/2016 603867 Till Mor repertusion njury of
the heal Miscellaneous 3003/2011 2014-258628 2015-57450 11111/2016 603867 Till Mor repertusion njury of
the heat Miscellaneous 3003/2011 13/630160 2015-57450 11111/2016 603867 Till Mor repertusion njury Winted States of 3003/2011 13/630160 2015-57450 11111/2016 603867 Till for repertusion njury Winted States of 3003/2011 13/630160 2015-57450 11111/2016 603867 Till for repertusion njury Winted States of 3003/2011 13/630160 2015-57450 11111/2016 603867 Till for repertusion njury Winteleault 3003/2011 <t< td=""><td>Till for repertusion njury of
the heart - Magnus OxyganUnited Kingetom3003/2010100534,00001/2015567/401567/401Till for repertusion njury of
the heartJapan3003/20112013-5018472013-523709080/1/2015567/401Till for repertusion njury of
the heartJapan3003/20112013-5018472013-523709080/1/2015567/401Till for repertusion njury of
the heartJapan3003/20112014-2586282015-57/45011/11/2016603867Till for repertusion njury of
the heartJapan3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njury of
the heartJapan3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njury of
the heartMaccilaneous3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njuryWorld Intelectual
and social3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njuryWorld Intelectual
and social3003/201113/6301802013-0177669911/11/2016603867United States of
terrationoxybotate and fsUnited States of
America21/10/20168/2/410.8882011/1213641Civitatiline
terrationoxybotate and fsUnited States of
America21/10/20168/2/410.88811Filammeeuficial UsesUnited States of
America21/10/20168/2/410.88811</td><td>TTM for repertision hjury of
the heart. Japan 50/03/2010 1005384.0 1005384.0 TTM for repertision hjury of
the heart. Japan 30/03/2011 2013-501947 2013-523709 080/1/2015 6674917 TTM for repertision hjury of
the heart. Japan 30/03/2011 2013-501947 2013-523709 080/1/2015 6674917 TTM for repertision hjury of
the heart. Japan 30/03/2011 2014-258028 2015-57.450 11/11/2016 6028667 TTM for repertusion hjury of
the heart. Mascellaneous 30/03/2011 13/630160 2013-6177669 11/11/2016 6028667 TTM for repertusion hjury
the heart. World Intelectual 30/03/2011 13/630160 2013-0177669 11/11/2016 6028667 TTM for repertusion hjury
the heart. World Intelectual 30/03/2011 13/630160 2013-0177669 11/11/2016 6028667 TTM for repertusion hjury
the heart. World Intelectual 30/03/2011 13/630160 2013-0177669 11/11/2016 6028667 TTM for repertusion hjury
the for repertusion hjury World Intelectual 30/03/2011 13/630160 2013-01712154 11/11/12/154 TTM for repertusion hjury
the maceutical Uses United States of
Anterica 21/10/2016 62/410.886 11/11/12154</td><td>3EP08666EP3</td><td>TTM for peripheral artery disease</td><td>European Patent
Office</td><td>30/03/2011</td><td></td><td></td><td></td><td></td><td>Never filed</td></t<> | Till for repertusion njury of
the heart - Magnus OxyganUnited Kingetom3003/2010100534,00001/2015567/401567/401Till for repertusion njury of
the heartJapan3003/20112013-5018472013-523709080/1/2015567/401Till for repertusion njury of
the heartJapan3003/20112013-5018472013-523709080/1/2015567/401Till for repertusion njury of
the heartJapan3003/20112014-2586282015-57/45011/11/2016603867Till for repertusion njury of
the heartJapan3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njury of
the heartJapan3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njury of
the heartMaccilaneous3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njuryWorld Intelectual
and social3003/201113/6301802015-57/45011/11/2016603867Till for repertusion njuryWorld Intelectual
and social3003/201113/6301802013-0177669911/11/2016603867United States of
terrationoxybotate and fsUnited States of
America21/10/20168/2/410.8882011/1213641Civitatiline
terrationoxybotate and fsUnited States of
America21/10/20168/2/410.88811Filammeeuficial UsesUnited States of
America21/10/20168/2/410.88811 | TTM for repertision hjury of
the heart. Japan 50/03/2010 1005384.0 1005384.0 TTM for repertision hjury of
the heart. Japan 30/03/2011 2013-501947 2013-523709 080/1/2015 6674917 TTM for repertision hjury of
the heart. Japan 30/03/2011 2013-501947 2013-523709 080/1/2015 6674917 TTM for repertision hjury of
the heart. Japan 30/03/2011 2014-258028 2015-57.450 11/11/2016 6028667 TTM for repertusion hjury of
the heart. Mascellaneous 30/03/2011 13/630160 2013-6177669 11/11/2016 6028667 TTM for repertusion hjury
the heart. World Intelectual 30/03/2011 13/630160 2013-0177669 11/11/2016 6028667 TTM for repertusion hjury
the heart. World Intelectual 30/03/2011 13/630160 2013-0177669 11/11/2016 6028667 TTM for repertusion hjury
the heart. World Intelectual 30/03/2011 13/630160 2013-0177669 11/11/2016 6028667 TTM for repertusion hjury
the for repertusion hjury World Intelectual 30/03/2011 13/630160 2013-01712154 11/11/12/154 TTM for repertusion hjury
the maceutical Uses United States of
Anterica 21/10/2016 62/410.886 11/11/12154 | 3EP08666EP3 | TTM for peripheral artery disease | European Patent
Office | 30/03/2011 | | | | | Never filed |
| TTM for repertusion injury of
the heart Japan 30/03/2011 2013-501947 2013-523709 09/01/2015 567/4917 TTM for repertusion injury of
the brain Japan 30/03/2011 2014-258628 2015-57450 11/11/2016 6038657 TTM for repertusion injury of
the brain Japan 30/03/2011 2014-258628 2015-57450 11/11/2016 6038657 TTM for repertusion injury of
the heart - Magnus Coxgen Miscellaneous 30/03/2011 13/630180 2015-57450 11/11/2016 6038657 TTM for repertusion injury of
the heart - Magnus Coxgen Miscellaneous 30/03/2011 13/630180 2015-57450 11/11/2016 6038667 TTM for repertusion injury United States of
America 30/03/2011 13/630180 2013-0117659 0031011/121354 0031011/121354 TTM for repertusion injury Property Organisation 30/03/2011 13/630180 2013-011/121354 0011/11/21354 Crystaline Diethylearnine United States of 21/10/2016 62/410.866 MO2011/11/21354 0011/11/21354 Crystaline Diethylearnine United States of 21/10/2016 62/410.866 0011/11/21354 0011/11/21354 001 | TTM for repertusion injury of
the heartJapen3003/20112013-5016472013-523709068/01/20155674917TTM for repertusion injury of
the brainJapan30/03/20112014-5586282015-5745011/11/20166038667TTM for repertusion injury of
the braint - Magnus OxygenMiscellaneous30/03/201113/6301802015-5745011/11/20166038667TTM for repertusion injury of
the braint - Magnus OxygenMiscellaneous30/03/201113/6301802015-5745011/11/20166038667TTM for repertusion injury
the braint - Magnus OxygenUnited States of
America30/03/201113/6301802015-017766911/11/20166038667TTM for repertusion injury
the braintUnited States of
Organisation30/03/201113/6301802015-017766911/11/20166038667TTM for repertusion injury
the braintUnited States of
Organisation30/03/201113/6301802015-017766911/11/20166038667TTM for repertusion injury
the braintUnited States of
Droperty30/03/201113/6301802015-0171050653WO2011112135411/11/2016Crystatiline Detriviee
Planamecutical basesUnited States of
America21/10/201662/410.86652/10.205611/11/201511/11/2016Planamecutical basesDistributioned basesDistributioned bases21/10/201662/410.86611/11/201611/11/201611/11/2016Planamecutical basesDistributioned basesDistributioned basesDistributioned bases21/10/2016 | TitM for repertuation injury of
the brain Japan 30/03/2011 2013-501947 2013-253709 09001/2015 567/417 TitM for repertuation injury of
the brain Japan 30/03/2011 2014-256828 2015-57/450 11/11/2016 637/417 TitM for repertuation injury of
the brain Miscellaneous 30/03/2011 2014-256828 2015-57/450 11/11/2016 63038667 TitM for repertuation injury of
the heart - Megnus Oxygen Wiscellaneous 30/03/2011 13/630180 2015-67/450 11/11/12016 63038667 TitM for repertuation injury United Statee of 30/03/2011 13/630180 2015-0177659 11/11/12016 63038667 TitM for repertuation injury Organisation 30/03/2011 13/630180 2015-0177659 11/11/12016 63038667 Corstatine Distribution United Statee of 21/10/2016 62/410.386 WO2011/121354 11/11/12016 63038667 Corstatine Distribution United Statee of 21/10/2016 62/410.386 MO2011/121354 11/11/12016 11/11/12016 Corstatine Distribution United Statee of 21/10/2016 62/410.386 11/11/201354 11/11/11/11/11/11/11/11/11/11/11/1 | TEP08666GB | TTM for reperfusion injury of
the heart - Magnus Oxygen | United Kingdom | 30/03/2010 | 1005394.0 | | | | Abandoned by client |
| TIM for repertusion injury of
the brain Japan 30/03/2011 2014-258628 2015-57450 11/11/2016 6038867 TIM for repertusion injury of
the heart - Magnus Oxygen Miscellaneous 30/03/2011 13/630180 2015-67450 11/11/2016 6038867 TIM for repertusion injury United States of
TIM for repertusion injury 30/03/2011 13/630180 2015-0177659 11/11/2016 6038867 TIM for repertusion injury World Intelectual 30/03/2011 13/630180 2013-0177659 11/11/20565 United States of
TIM for repertusion injury Organisation 30/03/2011 13/630180 2013-0177559 11/11/2015 Crystaffine Diethyleamine
Intraceutical Usee United States of
Diamaceutical Usee 21/10/2016 62/410.885 MO2011/121354 11/11/2015 | TTM for repertusion injury of
the brain Japan 30/03/2011 2014-258628 2015-57450 11/11/2016 6038667 TTM for repertusion injury of
the heart - Magnus Oxygen Misocilaneous 30/03/2011 13/630180 2013-0177659 8038667 TTM for repertusion injury of
the heart - Magnus Oxygen Misocilaneous 30/03/2011 13/630180 2013-0177659 8038667 TTM for repertusion injury
the heart - Magnus Oxygen United States of
America 30/03/2011 13/630180 2013-0177659 8003-0171121354 TTM for repertusion injury
treatition injury Orgenisation 30/03/2011 PCT/GB2011/050653 WOZ011/121354 80031/0111 Crystaline Diethylearnine
terratinonolydate and
the rest landecudical Uses United States of
America 21/10/2016 62/410.888 80 | TTM for reperfusion injury of the brain Japan 30/03/2011 2014-558628 2015-57450 11/11/2016 6038657 TM for reperfusion injury of the brain Mascellaneous Mascellaneous 30/03/2011 13/630160 2015-57450 11/11/2016 6038657 TM for reperfusion injury of the brain Mascellaneous 30/03/2011 13/630160 2015-01776659 003-01776559 003-01776559 003-01777555 TTM for reperfusion injury World fineliactual 30/03/2011 13/630160 2015-017775559 003-011/121354 00 | 1EP08666JP | TTM for reperfusion injury of
the heart | Јарап | 30/03/2011 | 2013-501947 | 2013-523709 | 09/01/2015 | 5674917 | Granted Radiotared |
| TM for repertusion injury of
the heart - Magnus Oxygen Miscellaneous TM for repertusion injury United States of
America 30/03/2011 13/630180 TM for repertusion injury United States of
America 30/03/2011 13/630180 TM for repertusion injury World Intellectual 30/03/2011 13/630180 Crystalline Diethylearnine
terrathiomolybdate and its
America 30/03/2011 PCT/GB2011/050653 2013-01/7659 | TIM for reperfusion injury of
the heart - Magnus Oxygen Miscelianeous TIM for reperfusion injury United States of
America 30/03/2011 13/630180 2013-0177659 TIM for reperfusion injury World Intellectual 30/03/2011 13/630180 2013-0177659 Crystatiline Diethylearnine United States of
Pharmaceutical Uses 30/03/2016 F2/110/205653 WO2011/121354 | TTM for reperfusion injury of
the heart. Magnus Oxygen Miscelianeous TTM for reperfusion injury United States of
America 30/03/2011 13/630180 2013-0177659 TTM for reperfusion injury World intellectual 30/03/2011 13/630180 2013-0177659 TTM for reperfusion injury Property 30/03/2011 PCT/CB2011/050653 2013-0177659 Crystalline Diethylearnine
tetrathiomolybdate and its United States of
America 21/10/2016 52/410.886 P | 3EP08666JP1 | TTM for reperfusion injury of
the brain | Japan | 30/03/2011 | 2014-258628 | 2015-57450 | 11/11/2016 | 6038867 | Granted/Registered |
| Th for repertusion injury United States of
America 30/03/2011 13/630180 2013-0177659 Th for reperfusion injury World Intellectual
Property 30/03/2011 13/630180 2013-0177659 Th for reperfusion injury Property 30/03/2011 PCT/GB2011/050653 2013-0177659 Crystalline Diethylearnine
terrathiomolybidate and its United States of
America 21/10/2016 62/410.885 | TTM for reperfusion injury United States of
America 30/03/2011 13/630180 2013-0177659 TTM for reperfusion injury World Intellectual 30/03/2011 13/630180 2013-0177659 TTM for reperfusion injury Property Organisation 30/03/2011 PCT/GB2011/0506653 2013-0177659 Crystalline Diethylearnine
terrathiomolybidate and its United States of
America 21/10/2016 52/410.886 52/410.886 | TTM for repertusion injury United States of
America 30/03/2011 13/630180 2013-0177659 TTM for repertusion injury World Intellectual 30/03/2011 13/630180 2013-0177659 TTM for repertusion injury Property 0rganisation 30/03/2011 PCT/GB2011/050653 WO2011/121354 Crystatiline Diethylearnine United States of
Pharmaceutical Uses 21/10/2016 52/410.866 WO2011/121354 | (E.P.08666Q.Q | TTM for reperfusion injury of the heart - Magnus Oxygen | Miscellaneous | | | | | - | Miscellaneous matter
underway |
| TM for reperfusion injury World Intellectual 30/03/2011 PCT/GB2011/050653 WO2011/121354 Crystatime Diethylearnine United States of 21/10/2016 62/410.885 Pharmaceutical Uses America 21/10/2016 62/410.885 | TM for reperfusion injury World Intellectual 30/03/2011 PCT/GB2011/050653 WO2011/121354 Crystatime Diethylearnine United States of 21/10/2016 52/410.885 Pharmaceutical Uses America 21/10/2016 52/410.885 | TM for reperfusion injury Vortid fintellectual 30/03/2011 PCT/CB2011/050663 W02011/121354 Property Organisation CTystalline Diethylearnine United States of 21/10/2016 62/410.886 M02011/121354 America America Diservetical Uses | (EPQ8666US | TTM for reperfusion injury | United States of
America | 30/03/2011 | 13/630180 | 2013-0177659 | | | Examination report received |
| United States of 21/10/2016 62/410.888 | United States of 21/10/2016 52/410.888 | 10/2016 62/410.888 | EP08666WO | TTM for reperfusion injury | World Intellectual
Property
Organisation | 30/03/2011 | PCT/CB2011/050853 | WO2011/121354 | | | Case Completed |
| | | | | Crystalline Diethyleamine
tetrathiomolybdate and its
Pharmaceutical Uses | United States of
America | 21/10/2016 | 62/410.888 | | | | Filed |

RECORDED: 10/02/2019